March 3, 2026Open Access

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes

Key Points

Recurrent limb events, cardiovascular events, and all-cause mortality were significantly lower with GLP-1 RAs.
Treatment with GLP-1 receptor agonists led to reduced risks over DPP-4 inhibitors in a high-risk group.
Cohort analysis of patients with diabetes previously experiencing major adverse limb events.
Findings support prioritizing GLP-1 RA use for better outcomes in this population.

Abstract

In this nationwide cohort study of patients with diabetes and prior MALEs, treatment with GLP-1 RAs was associated with significantly lower risks of recurrent limb events, cardiovascular events, all-cause mortality, and kidney disease progression compared with DPP-4 inhibitors. These findings support the preferential use of GLP-1 RAs for secondary prevention in this high-risk population.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Fu-Chih Hsiao

Tzyy-Jer Hsu

Yu-Jui Hsieh

Journals

JAMA Network Open

Actions

Institutions

Chang Gung University

Chang Gung Memorial Hospital

Linkou Chang Gung Memorial Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study